AL
NBIX icon

AJO LP’s Neurocrine Biosciences NBIX Stock Holding History

AJO LP’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,421
Closed -$958K – 714
2018
Q4 		$958K Sell
13,421
-26,956
-67% -$2.58M 0.01% 521
2018
Q3 		$4.96M Buy
40,377
+6,639
+20% +$753K 0.02% 357
2018
Q2 		$3.31M Buy
33,738
+24,452
+263% +$2.19M 0.02% 407
2018
Q1 		$770K Sell
9,286
-184
-2% -$15.5K ﹤0.01% 528
2017
Q4 		$735K Buy
+9,470
New +$646K ﹤0.01% 523
2015
Q3 		– Sell
-24,400
Closed -$1.17M – 543
2015
Q2 		$1.17M Buy
+24,400
New +$1.03M 0.01% 415

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AJO LP's NBIX Position: Q1 2019 in Review

AJO LP sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 13,421 shares — an estimated $958K sold.

AJO LP first reported a position in NBIX in Q2 2015 and held it in 6 quarters. The position peaked at $4.96M in Q3 2018. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • AJO LP reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
  • AJO LP sold 13,421 Neurocrine Biosciences shares in Q1 2019, an estimated $958K.
  • AJO LP first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 6 quarters.
  • AJO LP's Neurocrine Biosciences position peaked at $4.96M in Q3 2018.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on AJO LP's 13F filing for Q1 2019, filed 10 May 2019.